Molecular Context of theEGFRMutations: Evidence for the Activation of mTOR/S6K Signaling
- 1 February 2006
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 12 (3), 710-717
- https://doi.org/10.1158/1078-0432.ccr-05-1362
Abstract
Purpose: Histone acetyltransferases and histone deacetylases (HDAC) control the acetylation state of histones and other proteins regulating transcription and protein function. Several structurally diverse HDAC inhibitors have been developed as cancer therapeutic agents and in vitro have been shown to cause differentiation, cell cycle arrest, or apoptosis. Here, we have evaluated depsipeptide, a natural tetrapeptide HDAC inhibitor, against a panel of pediatric solid tumor models in vivo and evaluated pharmacokinetic and pharmacodynamic variables with tumor sensitivity.Keywords
This publication has 31 references indexed in Scilit:
- Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non–Small-Cell Lung CancerJNCI Journal of the National Cancer Institute, 2005
- Predictors of the Response to Gefitinib in Refractory Non–Small Cell Lung CancerClinical Cancer Research, 2005
- Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor in Non–Small Cell Lung CancerClinical Cancer Research, 2005
- Cyclin A as a Predictive Factor for Chemotherapy Response in Advanced Head and Neck CancerClinical Cancer Research, 2004
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinibProceedings of the National Academy of Sciences of the United States of America, 2004
- A Bull's Eye for Targeted Lung Cancer TherapyScience, 2004
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- The ErbB receptors and their role in cancer progressionExperimental Cell Research, 2003
- Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancersOncogene, 2002